Jiangsu Lianhuan Pharmaceutical (SHA:600513) obtained a supplementary drug approval for felodipine tablets after it passed the Chinese National Medical Products Administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.
The drug, which has the trade name Lianhuanerding, was tested for its consistency in quality and efficiency.
Felodipine tablets are used to treat mild to moderate essential hypertension, the pharmaceutical company said.
The company's shares slumped less than 7% at the close of Tuesday's trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments